ACRO Biomedical Co

ACRO Biomedical Co Debt / Assets

The Debt-to-Assets Ratio of ACRO Biomedical Co (6748.TWO) as of Oct 21, 2026 is 0.02. In the previous year, Debt-to-Assets Ratio was 0.03 — a change of -19.97% (lower).

Debt / Assets

0.02

YoY

-19.97%

Last updated:

Debt-to-Assets Ratio of ACRO Biomedical Co is 2024 0.02 . Debt-to-Assets Ratio of ACRO Biomedical Co was 2023 0.03 . It decreases by -19.97% lower compared to the previous year.

The ACRO Biomedical Co Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2018
0.00 TWD
Jan 1, 2019
0.11 TWD
Jan 1, 2020
0.08 TWD
Jan 1, 2021
0.09 TWD
Jan 1, 2022
0.03 TWD
Jan 1, 2023
0.03 TWD
Jan 1, 2024
0.02 TWD
The ACRO Biomedical Co Debt / Assets history
YEARDebt / AssetsYoY
0.02-19.97%
0.03+1.86%
0.03-66.42%
0.09+7.24%
0.08-23.73%
0.11—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ACRO Biomedical Co Stock analysis

What does ACRO Biomedical Co do? ACRO Biomedical Co., Ltd. generates revenue through the development and production of biomaterial medical devices, primarily focusing on collagen scaffolds for tissue engineering and regenerative medicine. The company offers products such as ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray, and ABCcolla External Aesthetic Restoration Prosthesis, all derived from pig skin and pig bone. These products are sold to healthcare providers and medical institutions involved in tissue engineering and regenerative medicine procedures. The firm also engages in international trade and technical services related to its products, expanding its market reach beyond local healthcare sectors. The company's revenue streams are driven by the sale of its specialized collagen-based medical devices, which are designed for applications in tissue repair and aesthetic restoration. ABCcolla Collagen Bone Graft targets bone regeneration, while ABCcolla Collagen Matrix and its variants support soft tissue engineering. ABCcolla Scar Spray addresses scar management, and the External Aesthetic Restoration Prosthesis serves cosmetic and reconstructive needs. These products cater to medical professionals seeking advanced solutions in regenerative medicine. ACRO Biomedical's business model relies on direct sales to healthcare institutions and international trade channels. The firm's focus on pig-derived collagen products positions it as a supplier for tissue engineering applications, with a strong emphasis on regenerative medicine. Technical services complement product sales, enhancing customer retention and recurring revenue opportunities. The company's product portfolio is tailored to meet the specific demands of medical professionals in tissue repair and aesthetic restoration markets. ACRO Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ACRO Biomedical Co stock

Debt-to-Assets Ratio of ACRO Biomedical Co is 0.02 in 2024.

Debt-to-Assets Ratio of ACRO Biomedical Co changed from 0.03 to 0.02, representing a -19.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio ACRO Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's ACRO Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ACRO Biomedical Co

All Key Metrics — ACRO Biomedical Co